The AHRQ Safety Program for
Methicillin-Resistant Staphylococcus aureus (MRSA) Prevention
New
collection (Request for a new OMB Control Number)
No
Regular
07/26/2021
Requested
Previously Approved
36 Months From Approved
36,637
0
11,552
0
0
0
As part of the HHS HAI National Action
Plan (NAP), AHRQ has supported the implementation and adoption of
the Comprehensive Unit-based Safety Program (CUSP) to reduce
Central-Line Associated Bloodstream Infections (CLABSI) and
Catheter-Associated Urinary Tract Infections (CAUTI), and
subsequently applied CUSP to other clinical challenges, including
reducing surgical site infections and improving care for
mechanically ventilated patients. As part of the National Action
Plan for Combating Antibiotic-Resistant Bacteria (CARB NAP), the
HHS HAI National Action Plan, and Healthy People 2030 goals, AHRQ
will now apply the principles and concepts that have been learned
from these HAI reduction efforts to the prevention of MRSA invasive
infections. Healthcare-associated infections, or HAIs, are a highly
significant cause of illness and death for patients in the U.S. At
any given time, HAIs affect one out of every 31 hospital
inpatients. More than a million of these infections occur across
our health care system every year. This leads to significant
patient harm and loss of life, and costs billions of dollars each
year in medical and non-medical costs. In addition, the 3 million
Americans currently residing in U.S. nursing homes experience a
staggering 2-3 million HAIs each year. Particular concern has
arisen related to the persistent prevalence of
methicillin-resistant Staphylococcus aureus (MRSA). This bacterium
affects both communities and healthcare facilities, but the
majority of morbidity and mortality occurs in critically and
chronically ill patients. While MRSA was rare in the US through the
1970s, its prevalence in US health care facilities began rising in
the 1980s and has continued to do so. In 2000, MRSA was responsible
for 133,510 hospitalizations in children and adults. This number
more than doubled by 2005, with 278,203 hospitalizations along with
56,248 septic events and 6,639 deaths being attributed to MRSA.
MRSA has become a major form of hospital-associated Staphylococcus
aureus infection. For various patient safety initiatives, AHRQ has
promoted the implementation and adoption of the Comprehensive
Unit-based Safety Program (CUSP) approach which combines clinical
and cultural (i.e., technical and adaptive) intervention components
to facilitate the implementation of technical bundles to improve
patient safety. For MRSA prevention, it is likely that a
combination of technical approaches is indicated, including
decolonization along with classic infection control practices such
as hand hygiene, environmental cleaning, general HAI prevention,
and contact precautions/isolation. Implementation of these
technical approaches would benefit greatly from the cultural and
behavioral interventions incorporated in CUSP. AHRQ expects that
this approach, which includes a focus on teamwork, communication,
and patient engagement, will enhance the effectiveness of
interventions to reduce MRSA infection that will be implemented and
evaluated as part of this project. This project will assist
hospital units and long-term care facilities in adopting and
implementing technical approaches to reduce MRSA infections. It
will be implemented in four cohorts: • at least 400 ICUs • at least
400 non-ICUs • at least 300 hospital surgical services • at least
300 long-term care facilities. The goals of this project are to 1)
develop and implement a program to prevent MRSA invasive infection
in intensive care units (ICUs), non-ICUs, inpatient surgery, and
long-term care facilities, 2) assess the adoption of CUSP for MRSA
Prevention, and 3) evaluate the effectiveness of the intervention
in the participating units.
US Code:
42
USC 299 Name of Law: Agency for Healthcare Research and Quality
Act of 1999
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.
Form 11 Attachment L: Clinical Outcomes Data for LTC
Supporting Statement A eb rev_21.07.23.mam.docx
Attachment L: Clinical Outcomes Data for LTC